ceftazidime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 559 72558-82-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ceftazidime hydrate
  • ceftazidime
  • biotum
  • cefazid
  • ceftacidin
  • ceftazidine
  • tazicef
  • tazidime
  • ceftazidime sodium
  • ceftazidime pentahydrate
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
  • Molecular weight: 547.58
  • Formula: C22H23N6O7S2
  • CLOGP: -3.47
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 4
  • TPSA: 188.39
  • ALOGS: -5.11
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P
6 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 156.82 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.31 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.79 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.80 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.911 High 0.83
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.685 High 0.83
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.406 10^-6 cm/s High 0.83
dh-clint Dog hepatocyte intrinsic clearance 1.963 uL/min/10^6 cells High 0.83
dppb Dog plasma protein binding (% unbound) 74.250 % High 0.83
fcs-ppb Fetal calf serum protein binding (% unbound) 61.260 % High 0.83
herg hERG pIC50 4.691 pIC50 High 0.83
hh-clint Human hepatocyte intrinsic clearance 2.244 uL/min/10^6 cells High 0.83
hlm-clint Human liver microsomal intrinsic clearance 4.055 uL/min/mg protein High 0.83
hppb Human plasma protein binding (% unbound) 62.020 % High 0.83
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 67
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK12,MAPK7,PRKDC,STK33,SYK,TEK,TGFBR1,TTK 19
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.303 Moderate 0.68
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.678 High 0.83
mh-clint Mouse hepatocyte intrinsic clearance 4.365 High 0.83
mppb Mouse plasma protein binding (% unbound) 79.100 High 0.83
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.069 High 0.83
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 63.370 % High 0.83
rat-kpuu-brain Rat brain Kpuu 0.013 % Moderate 0.68
rh-clint Rat hepatocyte intrinsic clearance 2.168 uL/min/10^6 cells High 0.83
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.290 % High 0.83
rppb Rat plasma protein binding (% unbound) 59.330 % High 0.83
solubility-dd Solubility at pH 7.4 in DMSO 914.113 uM High 0.83

Approvals:

DateAgencyCompanyOrphan
July 19, 1985 FDA COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aplastic anaemia 353.03 22.35 109 10842 13160 90604336
Endophthalmitis 165.80 22.35 48 10903 4637 90612859
Mucosal inflammation 132.41 22.35 84 10867 57541 90559955
Neutropenia 122.25 22.35 143 10808 224761 90392735
Multiple organ dysfunction syndrome 107.90 22.35 79 10872 68257 90549239
Acute kidney injury 103.58 22.35 158 10793 320229 90297267
Toxic epidermal necrolysis 102.18 22.35 58 10893 32470 90585026
Cholestasis 101.48 22.35 60 10891 36239 90581257
Drug resistance 100.27 22.35 56 10895 30393 90587103
Dysbiosis 100.07 22.35 26 10925 1676 90615820
Hyperbilirubinaemia 94.85 22.35 42 10909 13894 90603602
Pathogen resistance 91.16 22.35 35 10916 8080 90609416
Drug reaction with eosinophilia and systemic symptoms 89.98 22.35 59 10892 42699 90574797
Septic shock 89.25 22.35 77 10874 84083 90533413
Pseudomonas infection 89.11 22.35 41 10910 14824 90602672
Systemic inflammatory response syndrome 80.04 22.35 30 10921 6486 90611010
Rash maculo-papular 75.39 22.35 52 10899 40881 90576615
Graft versus host disease in gastrointestinal tract 71.89 22.35 25 10926 4363 90613133
Sepsis 70.11 22.35 97 10854 179717 90437779
Infective pulmonary exacerbation of cystic fibrosis 66.81 22.35 30 10921 10249 90607247
Pancytopenia 66.11 22.35 77 10874 120186 90497310
Graft versus host disease in skin 59.47 22.35 21 10930 3832 90613664
Fungaemia 58.43 22.35 20 10931 3330 90614166
Abscess 57.47 22.35 33 10918 18858 90598638
Febrile neutropenia 55.19 22.35 81 10870 158268 90459228
Thrombocytopenia 55.11 22.35 94 10857 208631 90408865
Paraspinal abscess 52.86 22.35 11 10940 264 90617232
Adenoviral hepatitis 52.77 22.35 12 10939 440 90617056
Intensive care unit acquired weakness 52.51 22.35 14 10937 997 90616499
Fungal sepsis 51.03 22.35 15 10936 1526 90615970
Endometrial disorder 50.49 22.35 13 10938 808 90616688
Hypopyon 49.11 22.35 13 10938 901 90616595
Enterococcus test positive 48.72 22.35 14 10937 1315 90616181
Disseminated intravascular coagulation 48.44 22.35 31 10920 21507 90595989
Fatigue 47.48 22.35 42 10909 1153981 89463515
Staphylococcal sepsis 47.38 22.35 23 10928 9360 90608136
Peritonitis 45.91 22.35 29 10922 19676 90597820
Patent ductus arteriosus 45.29 22.35 18 10933 4551 90612945
Bacterial sepsis 43.87 22.35 18 10933 4937 90612559
Neurotoxicity 43.64 22.35 29 10922 21438 90596058
Suspected transmission of an infectious agent via product 43.25 22.35 10 10941 395 90617101
Pseudomonal bacteraemia 43.12 22.35 14 10937 1980 90615516
Drug ineffective 42.75 22.35 299 10652 1383999 89233497
Arthralgia 41.83 22.35 21 10930 778501 89838995
Hepatic failure 41.38 22.35 36 10915 39692 90577804
Pyrexia 41.05 22.35 173 10778 660312 89957184
Hepatic cytolysis 40.50 22.35 32 10919 30884 90586612
Encephalopathy 40.34 22.35 38 10913 46406 90571090
Vanishing bile duct syndrome 39.56 22.35 12 10939 1360 90616136
Acute generalised exanthematous pustulosis 39.20 22.35 23 10928 13680 90603816
Transfusion 38.91 22.35 25 10926 17463 90600033
Drug ineffective for unapproved indication 38.83 22.35 44 10907 66600 90550896
Peripheral sensorimotor neuropathy 38.77 22.35 13 10938 2032 90615464
Alopecia 37.93 22.35 7 10944 495064 90122432
Stevens-Johnson syndrome 37.61 22.35 30 10921 29346 90588150
Myelosuppression 37.55 22.35 39 10912 53552 90563944
Micturition disorder 37.43 22.35 14 10937 3006 90614490
Myocardial calcification 36.99 22.35 8 10943 232 90617264
Respiratory failure 36.18 22.35 57 10894 118361 90499135
Venous haemorrhage 34.93 22.35 8 10943 303 90617193
Tubulointerstitial nephritis 34.86 22.35 27 10924 25316 90592180
Graft versus host disease in liver 34.66 22.35 10 10941 953 90616543
Pain 34.45 22.35 42 10909 996299 89621197
Mucormycosis 34.24 22.35 14 10937 3807 90613689
Ascites 33.91 22.35 35 10916 47705 90569791
Congestive hepatopathy 33.77 22.35 13 10938 3020 90614476
Cytomegalovirus infection 33.70 22.35 27 10924 26575 90590921
Escherichia infection 33.58 22.35 22 10929 15873 90601623
Pseudomonal sepsis 32.64 22.35 14 10937 4288 90613208
Graft versus host disease 32.43 22.35 17 10934 8127 90609369
Bronchopulmonary aspergillosis 32.25 22.35 19 10932 11379 90606117
Myelopathy 32.17 22.35 13 10938 3431 90614065
Clonus 31.79 22.35 15 10936 5735 90611761
Clostridium difficile colitis 31.50 22.35 26 10925 26680 90590816
Acinetobacter infection 31.20 22.35 11 10940 1997 90615499
Blood bilirubin increased 31.11 22.35 32 10919 43438 90574058
Off label use 30.96 22.35 233 10718 1102019 89515477
Aspergillus infection 30.52 22.35 18 10933 10805 90606691
Aplasia 30.32 22.35 13 10938 3978 90613518
Hypoproteinaemia 29.83 22.35 12 10939 3130 90614366
Renal impairment 29.81 22.35 49 10902 105372 90512124
Renal failure 29.40 22.35 55 10896 130952 90486544
Drug intolerance 29.04 22.35 9 10942 447582 90169914
Bacteraemia 29.03 22.35 23 10928 22277 90595219
Disseminated mucormycosis 28.82 22.35 8 10943 663 90616833
Fibrosis 28.29 22.35 14 10937 5938 90611558
Status epilepticus 27.92 22.35 21 10930 18853 90598643
Respiratory gas exchange disorder 27.73 22.35 7 10944 402 90617094
Myoclonus 27.63 22.35 21 10930 19147 90598349
Peripheral swelling 27.35 22.35 8 10943 413098 90204398
Peritonitis bacterial 27.09 22.35 13 10938 5158 90612338
Pulmonary haemorrhage 27.08 22.35 15 10936 7998 90609498
Hepatomegaly 27.07 22.35 18 10933 13308 90604188
Swelling 26.17 22.35 9 10942 419049 90198447
Systemic mycosis 26.16 22.35 9 10942 1521 90615975
Generalised oedema 25.55 22.35 20 10931 19033 90598463
Gamma-glutamyltransferase increased 25.48 22.35 27 10924 37925 90579571
Hypoaesthesia 25.02 22.35 4 10947 314206 90303290
Joint swelling 24.92 22.35 15 10936 503285 90114211
Cardiac arrest 24.73 22.35 45 10906 104890 90512606
Premature baby 24.66 22.35 22 10929 25055 90592441
Synovitis 24.52 22.35 5 10946 329747 90287749
Hepatic necrosis 24.39 22.35 13 10938 6425 90611071
Febrile bone marrow aplasia 24.37 22.35 15 10936 9723 90607773
Headache 24.25 22.35 42 10909 862704 89754792
Sweat test abnormal 24.17 22.35 4 10947 25 90617471
Hepatosplenic candidiasis 24.09 22.35 6 10945 326 90617170
Systemic lupus erythematosus 23.97 22.35 7 10944 361889 90255607
Eosinophilic pneumonia acute 23.85 22.35 7 10944 708 90616788
Poor quality product administered 23.84 22.35 11 10940 3997 90613499
Hepatocellular injury 23.83 22.35 23 10928 28935 90588561
Generalised bullous fixed drug eruption 23.56 22.35 6 10945 357 90617139
Linear IgA disease 22.68 22.35 9 10942 2265 90615231
Cardiomyopathy 22.44 22.35 19 10932 20187 90597309

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Choroiditis 236.72 18.52 61 14436 1314 42605524
Pathogen resistance 232.03 18.52 101 14396 11349 42595489
Aplastic anaemia 221.25 18.52 100 14397 12284 42594554
Septic shock 196.43 18.52 196 14301 91476 42515362
Multiple organ dysfunction syndrome 134.14 18.52 165 14332 96870 42509968
Eye pain 133.40 18.52 79 14418 16951 42589887
Intraocular pressure increased 131.11 18.52 57 14440 6376 42600462
Drug resistance 116.26 18.52 95 14402 34153 42572685
Hyperbilirubinaemia 112.23 18.52 76 14421 20559 42586279
Visual acuity reduced 108.44 18.52 70 14427 17480 42589358
Drug ineffective 106.96 18.52 459 14038 629738 41977100
Uveitis 105.56 18.52 55 14442 9203 42597635
Pseudomonas infection 102.07 18.52 65 14432 15858 42590980
Toxic epidermal necrolysis 92.45 18.52 75 14422 26675 42580163
Drug reaction with eosinophilia and systemic symptoms 86.33 18.52 88 14409 41987 42564851
Eosinophilia 77.12 18.52 74 14423 32825 42574013
Respiratory failure 76.90 18.52 148 14349 127984 42478854
Mucosal inflammation 76.39 18.52 89 14408 49285 42557553
Scedosporium infection 68.06 18.52 24 14473 1534 42605304
Fatigue 67.60 18.52 32 14465 435609 42171229
Endophthalmitis 64.26 18.52 31 14466 4402 42602436
Condition aggravated 58.48 18.52 208 14289 260546 42346292
Aspergillus infection 58.10 18.52 46 14451 15791 42591047
Vascular pseudoaneurysm thrombosis 54.13 18.52 11 14486 76 42606762
Candida infection 51.37 18.52 49 14448 21561 42585277
Fungal peritonitis 50.79 18.52 17 14480 928 42605910
Mycobacterium fortuitum infection 50.44 18.52 14 14483 403 42606435
Bronchopulmonary aspergillosis 47.98 18.52 45 14452 19384 42587454
Fall 47.14 18.52 11 14486 234509 42372329
Clostridium difficile colitis 46.41 18.52 46 14451 21206 42585632
Death 45.76 18.52 56 14441 471129 42135709
Febrile neutropenia 44.04 18.52 151 14346 185552 42421286
Disseminated intravascular coagulation 43.96 18.52 48 14449 24746 42582092
Cardiac valve vegetation 42.54 18.52 13 14484 528 42606310
Klebsiella infection 41.74 18.52 33 14464 11299 42595539
Mycobacterial peritonitis 41.42 18.52 10 14487 163 42606675
Rash maculo-papular 41.16 18.52 57 14440 37446 42569392
Fungal sepsis 40.83 18.52 15 14482 1079 42605759
Pyrexia 39.10 18.52 248 14249 393794 42213044
Product dose omission issue 38.29 18.52 4 14493 154361 42452477
Toxic skin eruption 38.20 18.52 34 14463 13696 42593142
Acute kidney injury 36.92 18.52 232 14265 367105 42239733
Fungaemia 36.80 18.52 19 14478 3117 42603721
Bradyarrhythmia 36.65 18.52 18 14479 2657 42604181
Dizziness 36.04 18.52 20 14477 249234 42357604
Trichosporon infection 35.33 18.52 13 14484 939 42605899
Drug ineffective for unapproved indication 32.25 18.52 57 14440 46106 42560732
Shock 31.56 18.52 44 14453 29077 42577761
Acute respiratory distress syndrome 30.42 18.52 44 14453 30064 42576774
Embolic cerebral infarction 28.84 18.52 11 14486 878 42605960
Clostridium difficile infection 28.78 18.52 37 14460 22622 42584216
Suspected transmission of an infectious agent via product 28.09 18.52 11 14486 943 42605895
Infective keratitis 28.02 18.52 6 14491 55 42606783
Wound drainage 27.43 18.52 10 14487 704 42606134
Acute generalised exanthematous pustulosis 27.38 18.52 23 14474 8572 42598266
Renal impairment 27.28 18.52 91 14406 110137 42496701
Anxiety 27.13 18.52 4 14493 118556 42488282
Respiratory distress 27.12 18.52 50 14447 41770 42565068
Guillain-Barre syndrome 26.43 18.52 21 14476 7242 42599596
Infective corneal ulcer 25.98 18.52 5 14492 25 42606813
Embolia cutis medicamentosa 25.69 18.52 8 14489 346 42606492
Pseudoendophthalmitis 25.64 18.52 6 14491 85 42606753
Cutaneous vasculitis 25.31 18.52 20 14477 6840 42599998
Depression 24.93 18.52 4 14493 111359 42495479
Graft versus host disease 24.62 18.52 26 14471 12899 42593939
Folliculitis 24.46 18.52 18 14479 5540 42601298
Blood pressure increased 24.36 18.52 3 14494 101925 42504913
Product contamination 24.20 18.52 10 14487 985 42605853
Herpes zoster reactivation 24.18 18.52 8 14489 421 42606417
Varicella virus test positive 24.10 18.52 7 14490 238 42606600
Pseudomonas test positive 23.56 18.52 11 14486 1452 42605386
Keratitis bacterial 23.51 18.52 6 14491 124 42606714
Proteus test positive 23.48 18.52 7 14490 261 42606577
Haemodynamic instability 23.46 18.52 25 14472 12532 42594306
Fungal infection 23.18 18.52 31 14466 19691 42587147
Pseudomembranous colitis 23.13 18.52 14 14483 3119 42603719
Arterial angioplasty 22.96 18.52 5 14492 50 42606788
Candida pneumonia 22.92 18.52 9 14488 777 42606061
Cerebrovascular accident 22.88 18.52 3 14494 97157 42509681
Hypopyon 22.45 18.52 8 14489 527 42606311
Febrile bone marrow aplasia 22.15 18.52 22 14475 10159 42596679
Bone marrow failure 22.00 18.52 40 14457 33053 42573785
Stomatitis 21.83 18.52 51 14446 50278 42556560
Pain 21.74 18.52 31 14466 244817 42362021
Liver abscess 21.66 18.52 16 14481 4954 42601884
Pseudomonal sepsis 21.55 18.52 15 14482 4234 42602604
Arteritis infective 21.29 18.52 5 14492 72 42606766
Chondritis 21.01 18.52 6 14491 192 42606646
Cholestasis 20.93 18.52 39 14458 32840 42573998
Listeriosis 20.85 18.52 10 14487 1401 42605437
Peripheral swelling 20.75 18.52 3 14494 90267 42516571
Leukopenia 20.56 18.52 64 14433 74682 42532156
Pain in extremity 20.45 18.52 13 14484 150591 42456247
Thrombocytopenia 20.18 18.52 122 14375 190157 42416681
Lichenoid keratosis 20.16 18.52 14 14483 3936 42602902
Off label use 20.06 18.52 316 14181 638019 41968819
Cystic fibrosis 20.02 18.52 11 14486 2044 42604794
Mycotic endophthalmitis 19.97 18.52 6 14491 230 42606608
Haemoperitoneum 19.96 18.52 11 14486 2055 42604783
Flavobacterium infection 19.79 18.52 5 14492 99 42606739
Aplasia 19.79 18.52 15 14482 4828 42602010
Product use issue 19.55 18.52 64 14433 76687 42530151
Neutropenia 19.35 18.52 125 14372 199306 42407532
Cardiac failure congestive 19.32 18.52 3 14494 85599 42521239
Myocardial infarction 19.32 18.52 9 14488 124000 42482838
Gastroenteritis staphylococcal 19.19 18.52 6 14491 263 42606575
Bacterial endophthalmitis 18.80 18.52 5 14492 122 42606716

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aplastic anaemia 566.53 17.44 209 23743 24099 110541248
Pathogen resistance 307.93 17.44 123 23829 17549 110547798
Septic shock 289.02 17.44 253 23699 157275 110408072
Choroiditis 259.44 17.44 62 23890 1553 110563794
Multiple organ dysfunction syndrome 231.91 17.44 220 23732 151490 110413857
Endophthalmitis 211.49 17.44 76 23876 8111 110557236
Drug resistance 209.19 17.44 138 23814 56236 110509111
Mucosal inflammation 197.79 17.44 165 23787 95976 110469371
Toxic epidermal necrolysis 186.89 17.44 129 23823 56598 110508749
Pseudomonas infection 181.41 17.44 98 23854 27755 110537592
Drug reaction with eosinophilia and systemic symptoms 179.53 17.44 146 23806 81949 110483398
Drug ineffective 174.17 17.44 718 23234 1519822 109045525
Hyperbilirubinaemia 172.58 17.44 98 23854 30573 110534774
Acute kidney injury 136.69 17.44 372 23580 635058 109930289
Visual acuity reduced 124.78 17.44 81 23871 32092 110533255
Intraocular pressure increased 123.86 17.44 56 23896 10820 110554527
Fatigue 121.57 17.44 56 23896 1215902 109349445
Respiratory failure 115.58 17.44 184 23768 215148 110350199
Neutropenia 113.07 17.44 250 23702 374370 110190977
Rash maculo-papular 108.29 17.44 105 23847 74117 110491230
Eye pain 107.17 17.44 88 23864 50011 110515336
Cholestasis 103.12 17.44 96 23856 64422 110500925
Eosinophilia 100.00 17.44 90 23862 57846 110507501
Fungaemia 91.08 17.44 38 23914 6048 110559299
Uveitis 87.49 17.44 56 23896 21654 110543693
Disseminated intravascular coagulation 87.21 17.44 72 23880 41214 110524133
Febrile neutropenia 86.20 17.44 203 23749 316564 110248783
Aspergillus infection 86.09 17.44 59 23893 25557 110539790
Bronchopulmonary aspergillosis 82.42 17.44 61 23891 29802 110535545
Sepsis 75.56 17.44 197 23755 327149 110238198
Clostridium difficile colitis 75.52 17.44 68 23884 43710 110521637
Pyrexia 73.10 17.44 385 23567 897880 109667467
Candida infection 70.16 17.44 68 23884 47941 110517406
Infective pulmonary exacerbation of cystic fibrosis 69.37 17.44 42 23910 14729 110550618
Pancytopenia 68.99 17.44 145 23807 209468 110355879
Suspected transmission of an infectious agent via product 68.31 17.44 21 23931 1379 110563968
Scedosporium infection 67.95 17.44 24 23928 2434 110562913
Pain 67.01 17.44 65 23887 954890 109610457
Drug ineffective for unapproved indication 66.64 17.44 96 23856 102742 110462605
Fungal sepsis 66.28 17.44 23 23929 2214 110563133
Thrombocytopenia 65.73 17.44 195 23757 348690 110216657
Renal impairment 63.93 17.44 132 23820 188313 110377034
Acute generalised exanthematous pustulosis 63.74 17.44 46 23906 21618 110543729
Arthralgia 62.06 17.44 47 23905 779585 109785762
Fall 61.35 17.44 27 23925 603455 109961892
Dizziness 61.00 17.44 38 23914 698155 109867192
Fungal peritonitis 60.96 17.44 19 23933 1306 110564041
Klebsiella infection 60.04 17.44 43 23909 19966 110545381
Hypopyon 59.40 17.44 19 23933 1421 110563926
Mycobacterial peritonitis 58.68 17.44 13 23939 230 110565117
Vascular pseudoaneurysm thrombosis 58.59 17.44 11 23941 80 110565267
Abdominal discomfort 58.50 17.44 8 23944 393850 110171497
Peripheral swelling 58.17 17.44 9 23943 404025 110161322
Encephalopathy 57.46 17.44 79 23873 80976 110484371
Graft versus host disease in gastrointestinal tract 56.83 17.44 31 23921 8937 110556410
Off label use 56.65 17.44 533 23419 1499652 109065695
Graft versus host disease in skin 56.41 17.44 30 23922 8224 110557123
Pseudomonal bacteraemia 54.55 17.44 24 23928 4347 110561000
Drug intolerance 54.29 17.44 11 23941 406501 110158846
Mycobacterium fortuitum infection 54.18 17.44 14 23938 486 110564861
Toxic skin eruption 54.00 17.44 46 23906 27469 110537878
Systemic inflammatory response syndrome 53.43 17.44 34 23918 13009 110552338
Graft versus host disease 53.21 17.44 39 23913 18767 110546580
Alopecia 52.79 17.44 8 23944 364745 110200602
Dysbiosis 52.10 17.44 19 23933 2113 110563234
Product dose omission issue 51.61 17.44 5 23947 321777 110243570
Joint swelling 51.39 17.44 16 23936 442829 110122518
Pain in extremity 50.75 17.44 21 23931 487097 110078250
Intensive care unit acquired weakness 50.22 17.44 19 23933 2340 110563007
Aplasia 49.30 17.44 27 23925 7846 110557501
Headache 49.12 17.44 72 23880 882305 109683042
Cardiac valve vegetation 48.21 17.44 15 23937 1025 110564322
Stevens-Johnson syndrome 48.10 17.44 55 23897 46846 110518501
Multiple-drug resistance 48.09 17.44 32 23920 13203 110552144
Swelling 47.92 17.44 9 23943 351032 110214315
Shock 46.97 17.44 58 23894 53530 110511817
Transfusion 46.78 17.44 41 23911 25431 110539916
Status epilepticus 46.66 17.44 45 23907 31526 110533821
Product contamination 46.41 17.44 17 23935 1914 110563433
Muscle spasms 45.46 17.44 4 23948 278153 110287194
Endometrial disorder 45.17 17.44 13 23939 679 110564668
Poor quality product administered 43.84 17.44 21 23931 4620 110560727
Pseudomonas test positive 43.13 17.44 17 23935 2337 110563010
Synovitis 42.06 17.44 5 23947 274087 110291260
Paraspinal abscess 41.69 17.44 11 23941 415 110564932
Therapeutic product effect decreased 41.36 17.44 3 23949 244313 110321034
Nasopharyngitis 41.07 17.44 17 23935 394344 110171003
Anxiety 40.87 17.44 12 23940 345066 110220281
Musculoskeletal stiffness 40.79 17.44 6 23946 279816 110285531
Neurotoxicity 40.78 17.44 48 23904 42159 110523188
Pseudomonal sepsis 40.63 17.44 25 23927 9021 110556326
Contraindicated product administered 39.43 17.44 4 23948 248263 110317084
Wound 39.34 17.44 3 23949 234434 110330913
Bacterial endophthalmitis 39.13 17.44 10 23942 332 110565015
Renal tubular necrosis 38.69 17.44 40 23912 30435 110534912
Respiratory distress 38.47 17.44 60 23892 68814 110496533
Systemic mycosis 38.23 17.44 18 23934 3811 110561536
Paraesthesia 37.92 17.44 7 23945 276514 110288833
Bacterial sepsis 37.38 17.44 25 23927 10401 110554946
Peritonitis bacterial 37.15 17.44 25 23927 10508 110554839
Trichosporon infection 37.11 17.44 13 23939 1287 110564060
Hypoaesthesia 37.08 17.44 11 23941 314212 110251135
Acute respiratory distress syndrome 36.42 17.44 51 23901 53147 110512200
Adenoviral hepatitis 36.26 17.44 12 23940 1000 110564347
Contusion 34.02 17.44 5 23947 233356 110331991
Lower respiratory tract infection 33.67 17.44 6 23946 243100 110322247
Enterococcus test positive 33.21 17.44 15 23937 2889 110562458
Venoocclusive liver disease 33.11 17.44 27 23925 15180 110550167
Myelosuppression 33.04 17.44 67 23885 94273 110471074
Mobility decreased 32.58 17.44 6 23946 237416 110327931
Hepatocellular injury 32.39 17.44 47 23905 50595 110514752
Fungal infection 32.27 17.44 47 23905 50759 110514588
Mucormycosis 32.25 17.44 23 23929 10605 110554742
Sinusitis 32.18 17.44 12 23940 296676 110268671
Staphylococcal sepsis 31.86 17.44 28 23924 17426 110547921
Febrile bone marrow aplasia 31.85 17.44 28 23924 17437 110547910
Cystic fibrosis 31.78 17.44 17 23935 4714 110560633
Memory impairment 31.72 17.44 3 23949 196941 110368406
Leukopenia 31.69 17.44 87 23865 148704 110416643
Myocardial calcification 31.53 17.44 8 23944 258 110565089
Device related sepsis 31.49 17.44 20 23932 7627 110557720
Retinal vasculitis 31.35 17.44 13 23939 2036 110563311
Hepatic necrosis 31.33 17.44 22 23930 9900 110555447
Pericarditis 31.24 17.44 5 23947 219109 110346238
Bradyarrhythmia 31.11 17.44 17 23935 4917 110560430
Insomnia 30.92 17.44 20 23932 360570 110204777
Ascites 30.26 17.44 64 23888 92744 110472603
Tubulointerstitial nephritis 29.91 17.44 47 23905 54237 110511110
Staphylococcal infection 29.82 17.44 54 23898 69890 110495457
Dry mouth 29.81 17.44 4 23948 199944 110365403
Escherichia infection 29.77 17.44 31 23921 23785 110541562
Guillain-Barre syndrome 29.76 17.44 22 23930 10722 110554625
Renal failure 29.58 17.44 112 23840 226462 110338885
Abscess 29.50 17.44 33 23919 27436 110537911
Platelet count decreased 29.33 17.44 113 23839 230330 110335017
Micturition disorder 29.11 17.44 16 23936 4682 110560665
Malaise 29.08 17.44 64 23888 671755 109893592
Haemophagocytic lymphohistiocytosis 29.02 17.44 35 23917 31524 110533823
Peripheral sensorimotor neuropathy 28.85 17.44 15 23937 3928 110561419
Venous haemorrhage 28.76 17.44 8 23944 369 110564978
Condition aggravated 28.48 17.44 263 23689 734573 109830774
Cytomegalovirus infection 28.43 17.44 46 23906 54398 110510949
Pseudoendophthalmitis 28.40 17.44 6 23946 84 110565263
Hepatosplenic candidiasis 28.35 17.44 9 23943 657 110564690
Infective corneal ulcer 28.24 17.44 5 23947 25 110565322
Systemic lupus erythematosus 28.07 17.44 10 23942 254328 110311019
Embolic cerebral infarction 28.03 17.44 11 23941 1495 110563852
Injection site pain 27.90 17.44 3 23949 177919 110387428
Myoclonus 27.77 17.44 35 23917 32963 110532384
Type 2 diabetes mellitus 27.77 17.44 3 23949 177229 110388118
Keratitis bacterial 27.34 17.44 7 23945 234 110565113
Platelet transfusion 27.25 17.44 13 23939 2833 110562514
Pseudomembranous colitis 27.03 17.44 17 23935 6374 110558973
Impaired healing 26.92 17.44 5 23947 196712 110368635
Infective keratitis 26.68 17.44 6 23946 114 110565233
Weight increased 26.62 17.44 31 23921 419613 110145734
Peritonitis 26.51 17.44 34 23918 32573 110532774
Neutrophil count decreased 26.03 17.44 71 23881 120870 110444477
Wound drainage 25.95 17.44 10 23942 1294 110564053
Parenteral nutrition 25.69 17.44 9 23943 891 110564456
Noninfectious peritonitis 25.57 17.44 7 23945 304 110565043
Blood bilirubin increased 25.48 17.44 53 23899 75919 110489428
Intentional product use issue 25.29 17.44 11 23941 247895 110317452
Arterial angioplasty 25.21 17.44 5 23947 50 110565297
Corneal perforation 25.16 17.44 9 23943 947 110564400
Hypogonadism 25.05 17.44 11 23941 1983 110563364
Acinetobacter infection 24.45 17.44 13 23939 3560 110561787
Pneumonia pseudomonal 24.45 17.44 17 23935 7529 110557818
Fibrosis 24.26 17.44 17 23935 7625 110557722
Liver abscess 24.07 17.44 17 23935 7722 110557625
Cerebrovascular accident 23.98 17.44 5 23947 181279 110384068
Rheumatoid arthritis 23.86 17.44 18 23934 299595 110265752
Varicella virus test positive 23.80 17.44 7 23945 395 110564952
Acute respiratory failure 23.50 17.44 51 23901 75209 110490138
Moraxella infection 23.13 17.44 8 23944 762 110564585
Hypoproteinaemia 23.12 17.44 15 23937 5930 110559417
Hepatic failure 23.10 17.44 48 23904 68691 110496656
Mycotic endophthalmitis 23.08 17.44 7 23945 439 110564908
Corneal oedema 23.01 17.44 12 23940 3161 110562186
Clostridium test positive 23.00 17.44 19 23933 10874 110554473
Hepatic function abnormal 22.91 17.44 56 23896 89239 110476108
Scleromalacia 22.54 17.44 5 23947 89 110565258
Musculoskeletal pain 22.34 17.44 6 23946 183017 110382330
Infusion related reaction 22.24 17.44 30 23922 381132 110184215
Vitritis 22.05 17.44 11 23941 2642 110562705
Clostridium difficile infection 21.91 17.44 40 23912 52089 110513258
Generalised oedema 21.86 17.44 30 23922 30674 110534673
Ill-defined disorder 21.43 17.44 4 23948 156849 110408498
Injury 21.28 17.44 6 23946 177259 110388088
Gastroenteritis staphylococcal 20.85 17.44 6 23946 313 110565034
Inappropriate schedule of product administration 20.83 17.44 9 23943 203628 110361719
Flavobacterium infection 20.70 17.44 5 23947 131 110565216
Nausea 20.69 17.44 170 23782 1235520 109329827
Cutaneous vasculitis 20.44 17.44 19 23933 12710 110552637
Myocardial infarction 20.44 17.44 8 23944 192075 110373272
Hepatic cytolysis 20.35 17.44 40 23912 55013 110510334
Dyspepsia 20.24 17.44 8 23944 190957 110374390
Vanishing bile duct syndrome 20.21 17.44 11 23941 3157 110562190
Feeling abnormal 20.11 17.44 7 23945 180704 110384643
Ototoxicity 20.05 17.44 12 23940 4119 110561228
Nocardiosis 20.00 17.44 15 23937 7471 110557876
Lichenoid keratosis 19.96 17.44 14 23938 6288 110559059
Congestive hepatopathy 19.88 17.44 13 23939 5207 110560140
Abdominal pain upper 19.84 17.44 28 23924 349083 110216264
Graft versus host disease in liver 19.84 17.44 10 23942 2455 110562892
Sweat test abnormal 19.82 17.44 4 23948 44 110565303
Bacteraemia 19.71 17.44 34 23918 42356 110522991
Discomfort 19.67 17.44 11 23941 214696 110350651
Hypokalaemia 19.67 17.44 85 23867 182363 110382984
Geotrichum infection 19.60 17.44 8 23944 1204 110564143
Proteus test positive 19.53 17.44 7 23945 741 110564606
Skin exfoliation 19.41 17.44 52 23900 87599 110477748
Pruritus 19.39 17.44 63 23889 581497 109983850
Choroidal detachment 19.31 17.44 7 23945 765 110564582
Arteritis infective 19.15 17.44 5 23947 181 110565166
Myelopathy 19.10 17.44 13 23939 5563 110559784
Bone marrow failure 18.98 17.44 40 23912 57808 110507539
Product preparation error 18.96 17.44 17 23935 10862 110554485
Listeriosis 18.59 17.44 10 23942 2804 110562543
Alanine aminotransferase increased 18.58 17.44 84 23868 183689 110381658
Hypoxia 18.55 17.44 66 23886 129449 110435898
Bursitis 18.44 17.44 3 23949 129915 110435432
Gastrooesophageal reflux disease 18.33 17.44 8 23944 179968 110385379
Burkholderia cepacia complex infection 18.33 17.44 6 23946 483 110564864
White blood cell count decreased 18.30 17.44 98 23854 229292 110336055
Systemic candida 18.20 17.44 16 23936 9958 110555389
Fungal abscess central nervous system 18.16 17.44 5 23947 222 110565125
Clonus 17.98 17.44 15 23937 8701 110556646
Enterococcal infection 17.77 17.44 22 23930 20344 110545003
Eye excision 17.74 17.44 4 23948 77 110565270
Blister 17.66 17.44 14 23938 227362 110337985
Chondritis 17.51 17.44 5 23947 254 110565093
Device related infection 17.47 17.44 31 23921 39488 110525859

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DD02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:50696 EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
CHEBI has role CHEBI:88188 drug allergen
MeSH PA D000097902 beta Lactam Antibiotics
MeSH PA D000097911 Third Generation Cephalosporins
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents

Related Drugs by ATC class:

J01DD Third-generation cephalosporins 17 drugs
cefcapenecefdinircefditoren pivoxilcefetametcefiximecefmenoximecefodizimecefoperazonecefotaximecefpiramidecefpodoxime proxetilcefsulodin show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Gonococcal meningitis indication 151004
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Ecthyma gangrenosum indication 17732003
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Pneumonia due to Streptococcus indication 34020007
Pneumonia due to Pseudomonas indication 41381004
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Endometritis indication 78623009 DOID:1002
Septicemia due to Serratia indication 82091000
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Meningococcal meningitis indication 192644005
Proteus pneumonia indication 195888009
Neonatal meningitis indication 276674008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Sepsis due to Staphylococcus aureus indication 448417001
Sepsis due to Pseudomonas indication 448813005
Urinary tract infection caused by Klebsiella indication 369001000119100
H. Influenzae Meningitis indication
Enterobacter Osteomyelitis indication
E. Coli Cervicitis indication
Pseudomonas Aeruginosa Joint Infection indication
Pseudomonas Aeruginosa Osteomyelitis indication
E. Coli Pelvic Inflammatory Disease indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Complicated Proteus UTI indication
E. Coli Gynecological Infections indication
Skin and Skin Structure Proteus Infection indication
E. Coli Endometritis indication
Haemophilus Septicemia indication
Klebsiella Pneumoniae Peritonitis indication
Inflammatory Disease of Female Pelvic Organs indication
Skin and Skin Structure Serratia Infection indication
Enterobacter Pneumonia indication
E. Coli Pelvic Cellulitis indication
EnterobacterJoint Infection indication
Staphylococcus Aureus Joint Infection indication
Staphylococcus Peritonitis indication
Klebsiella Pneumoniae Osteomyelitis indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Klebsiella Joint Infection indication
E. Coli Peritonitis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Citrobacter Pneumonia indication
Pyrexia of unknown origin off-label use 7520000
Pseudotuberculosis off-label use 36753006
Infection by Yersinia enterocolitica off-label use 80960004
Melioidosis off-label use 428111003 DOID:5052
Ventilator-acquired pneumonia off-label use 429271009
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Diabetic Foot Infection off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.53 acidic
pKa2 3.47 acidic
pKa3 13.61 acidic
pKa4 3.1 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ABBVIE N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ABBVIE N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ABBVIE N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ABBVIE N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS, COMPLICATED URINARY TRACT INFECTIONS, AND HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (AT LEAST 31 WEEKS GESTATIONAL AGE)

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ABBVIE N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS Jan. 26, 2027 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 6.26 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.53 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 4.96 WOMBAT-PK CHEMBL

External reference:

IDSource
4017550 VUID
N0000145931 NUI
D00921 KEGG_DRUG
78439-06-2 SECONDARY_CAS_RN
73547-61-2 SECONDARY_CAS_RN
203418 RXNORM
C0007559 UMLSCUI
CHEBI:3509 CHEBI
CHEMBL44354 ChEMBL_ID
CHEMBL1200768 ChEMBL_ID
D002442 MESH_DESCRIPTOR_UI
DB00438 DRUGBANK_ID
10762 IUPHAR_LIGAND_ID
9M416Z9QNR UNII
5481173 PUBCHEM_CID
1047 MMSL
173313 MMSL
2299 MMSL
2303 MMSL
30973 MMSL
4383 MMSL
4384 MMSL
d00009 MMSL
002735 NDDF
006723 NDDF
006724 NDDF
36893000 SNOMEDCT_US
387200005 SNOMEDCT_US
725671004 SNOMEDCT_US
4017550 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5082 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 24 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5084 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5086 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 24 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5092 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5093 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 25 sections
AVYCAZ HUMAN PRESCRIPTION DRUG LABEL 2 0456-2700 POWDER, FOR SOLUTION 2 g INTRAVENOUS NDA 30 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-129 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 27 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 44567-235 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 44567-236 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 44567-237 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 25 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-105 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAMUSCULAR NDA 24 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-106 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAMUSCULAR NDA 24 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-107 INJECTION, POWDER, FOR SOLUTION 170 mg INTRAMUSCULAR NDA 24 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-109 INJECTION, POWDER, FOR SOLUTION 200 mg INTRAMUSCULAR NDA 25 sections